NCT02963948

Brief Summary

This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropriate interventions by providing clinical decision support (CDS) and a mechanism for making referrals to addiction treatment. Investigators aim to maximize the efficient adoption of screening, CDS, and treatment referrals by integrating all of these activities into the electronic health record (EHR). The study will be conducted at three sites, representing three large health systems. Each phase will include deliverables essential to move to the next phase, and an independent Advisory Committee will review progress and make recommendations at each transition about how best to progress to each subsequent phase. Based on progress during earlier phases, the Advisory Committee may recommend expansion to additional clinics or health systems during the second part of Phase 4.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
113,123

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 10, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 15, 2016

Completed
1.3 years until next milestone

Study Start

First participant enrolled

February 28, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 9, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 9, 2019

Completed
Last Updated

August 29, 2022

Status Verified

August 1, 2022

Enrollment Period

1.5 years

First QC Date

November 10, 2016

Last Update Submit

August 24, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Adoption of screening

    % patients presenting for primary care visits who were screened in the past 12 months

    12 Months

  • Provider adoption of CDS

    % patients with positive screens for which CDS was launched and completed

    12 Months

  • Referral of high risk patients

    % patients with high risk use who received referral to specialty care

    12 Months

Study Arms (6)

Clinic A1

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Clinic A2

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Clinic B1

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Clinic B2

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Clinic B3

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Clinic B4

Behavioral: Meetings with implementation leader(s)Behavioral: the SAAS surveyBehavioral: Patient surveys

Interventions

The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.

Clinic A1Clinic A2Clinic B1Clinic B2Clinic B3Clinic B4
the SAAS surveyBEHAVIORAL

Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.

Clinic A1Clinic A2Clinic B1Clinic B2Clinic B3Clinic B4
Patient surveysBEHAVIORAL

Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months

Clinic A1Clinic A2Clinic B1Clinic B2Clinic B3Clinic B4

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Number of subjects: * Approximately 40 medical staff will be enrolled for the focus groups * Approximately 100 medical staff will be surveyed using Substance Abuse Attitude Survey (SAAS) * Approximately 200 patients at a Wave 1 clinic Clinical implementation leaders Clinical implementation leaders are practicing primary care physicians (PCPs) who provide feedback to the research team and support their colleagues on implementing screening, using the CDS, and carrying out clinical interventions and referrals to address unhealthy substance use. One or two primary care providers will be identified from each participating clinic will advise the research team on implementation and to serve as a resource for their colleagues.

You may qualify if:

  • English speaking adult individuals age 18 years or older, and current employee or patient at a Wave 1 clinic with direct patient contact.

You may not qualify if:

  • Inability to provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

Related Publications (1)

  • McNeely J, Adam A, Rotrosen J, Wakeman SE, Wilens TE, Kannry J, Rosenthal RN, Wahle A, Pitts S, Farkas S, Rosa C, Peccoralo L, Waite E, Vega A, Kent J, Craven CK, Kaminski TA, Firmin E, Isenberg B, Harris M, Kushniruk A, Hamilton L. Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics. JAMA Netw Open. 2021 May 3;4(5):e2110721. doi: 10.1001/jamanetworkopen.2021.10721.

MeSH Terms

Conditions

Substance-Related Disorders

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental Disorders

Study Officials

  • Jennifer McNeely, PhD

    New York University Medical School

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2016

First Posted

November 15, 2016

Study Start

February 28, 2018

Primary Completion

September 9, 2019

Study Completion

September 9, 2019

Last Updated

August 29, 2022

Record last verified: 2022-08

Locations